Terumo Acquires Exclusive Sales Rights for Three Contrast Agents from Guerbet AG.Tokyo, Japan, Oct 17, 2005 - (JCNN) - Terumo (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4543) announced on October 17 that it has signed an exclusive licensing agreement with Guerbet AG, a French manufacturer and distributor of contrast agents, for Under the agreement terms, Terumo acquires the Japan sales rights to three contrast agents: Magnescope Syringe for MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. , Hexabrix 320 for urography urography /urog·ra·phy/ (u-rog´rah-fe) radiography of any part of the urinary tract. ascending urography , cystoscopic urography retrograde u. and angiography, and Lipiodol Ultra-Fluide for lymphography lymphography /lym·phog·ra·phy/ (lim-fog´rah-fe) radiography of the lymphatic channels and lymph nodes after injection of radiopaque material. lym·phog·ra·phy n. See lymphangiography. and uterosalpingography. Terumo will start sales on January 1, 2006. With this move, the company aims to increase its presences in Japan. Currently, Magnescope Syringe and Hexabrix 320 is marketed by Tanabe Seiyaku and Lipiodo Ultra-Fluide by Nihon Schering. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion